TR200003198T2 - sPLA2 önleyicisi ester - Google Patents

sPLA2 önleyicisi ester

Info

Publication number
TR200003198T2
TR200003198T2 TR2000/03198T TR200003198T TR200003198T2 TR 200003198 T2 TR200003198 T2 TR 200003198T2 TR 2000/03198 T TR2000/03198 T TR 2000/03198T TR 200003198 T TR200003198 T TR 200003198T TR 200003198 T2 TR200003198 T2 TR 200003198T2
Authority
TR
Turkey
Prior art keywords
spla2 inhibitor
inhibitor ester
ester
spla2
dioxoethyl
Prior art date
Application number
TR2000/03198T
Other languages
English (en)
Turkish (tr)
Inventor
Lyle Denney Michael
John Michael Morin, Jr.
Jon Sall Daniel
Scott Sawyer Jason
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200003198T2 publication Critical patent/TR200003198T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TR2000/03198T 1998-05-01 1999-04-20 sPLA2 önleyicisi ester TR200003198T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01

Publications (1)

Publication Number Publication Date
TR200003198T2 true TR200003198T2 (tr) 2001-03-21

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03198T TR200003198T2 (tr) 1998-05-01 1999-04-20 sPLA2 önleyicisi ester

Country Status (22)

Country Link
EP (1) EP1073440B1 (cg-RX-API-DMAC10.html)
JP (1) JP4459441B2 (cg-RX-API-DMAC10.html)
KR (1) KR20010071197A (cg-RX-API-DMAC10.html)
CN (1) CN1303290A (cg-RX-API-DMAC10.html)
AT (1) ATE280155T1 (cg-RX-API-DMAC10.html)
AU (1) AU755901B2 (cg-RX-API-DMAC10.html)
BR (1) BR9910149A (cg-RX-API-DMAC10.html)
CA (1) CA2331036A1 (cg-RX-API-DMAC10.html)
DE (1) DE69921314T2 (cg-RX-API-DMAC10.html)
EA (1) EA003277B1 (cg-RX-API-DMAC10.html)
ES (1) ES2230847T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20000738A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0201636A1 (cg-RX-API-DMAC10.html)
ID (1) ID27812A (cg-RX-API-DMAC10.html)
IL (1) IL139203A0 (cg-RX-API-DMAC10.html)
NO (1) NO315940B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ507391A (cg-RX-API-DMAC10.html)
PL (1) PL344571A1 (cg-RX-API-DMAC10.html)
SK (1) SK16332000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200003198T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999056752A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200005561B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
EP2154958A4 (en) * 2007-05-03 2011-05-04 Anthera Pharmaceuticals Inc TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20150335498A1 (en) * 2014-05-22 2015-11-26 The Procter & Gamble Company Heterogenous mass containing foam
US10729600B2 (en) 2015-06-30 2020-08-04 The Procter & Gamble Company Absorbent structure
PL3370664T3 (pl) 2015-11-04 2022-03-07 The Procter & Gamble Company Wyrób chłonny zawierający strukturę chłonną
WO2017079599A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure
WO2017079605A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Method for determining bunch compression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis

Also Published As

Publication number Publication date
NO20005477D0 (no) 2000-10-31
NO20005477L (no) 2000-10-31
WO1999056752A1 (en) 1999-11-11
JP4459441B2 (ja) 2010-04-28
ES2230847T3 (es) 2005-05-01
EP1073440A4 (en) 2002-07-17
AU755901B2 (en) 2003-01-02
DE69921314D1 (de) 2004-11-25
HUP0201636A1 (en) 2002-09-28
DE69921314T2 (de) 2006-02-09
IL139203A0 (en) 2001-11-25
PL344571A1 (en) 2001-11-05
JP2002513761A (ja) 2002-05-14
EP1073440A1 (en) 2001-02-07
BR9910149A (pt) 2001-10-02
AU3652599A (en) 1999-11-23
EA200001141A1 (ru) 2001-04-23
KR20010071197A (ko) 2001-07-28
NO315940B1 (no) 2003-11-17
SK16332000A3 (sk) 2001-06-11
ZA200005561B (en) 2002-01-10
ATE280155T1 (de) 2004-11-15
EA003277B1 (ru) 2003-04-24
ID27812A (id) 2001-04-26
NZ507391A (en) 2003-12-19
HRP20000738A2 (en) 2001-10-31
CA2331036A1 (en) 1999-11-11
EP1073440B1 (en) 2004-10-20
CN1303290A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
ATE296286T1 (de) Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer
Kojima et al. A new and highly sensitive fluorescence assay for collagenase-like peptidase activity
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ATE422895T1 (de) Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
ID27812A (id) ESTER PENGHAMBAT sPLA2
PL365668A1 (en) Inhibitors of alpha4 mediated cell adhesion
DK1265606T3 (da) Celleadhæsionsinhibitorer
BR0317520A (pt) Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
TR200103017T2 (tr) Düşük molekül ağırlıklı trombin önleyici içeren formülasyon
DK51087A (da) Antihypercholesterolaemiske forbindelser
AP2002002554A0 (en) Ox (ADI) azolyl-hydroxamic acids useful as procollagen C- proteinase inhibitors.
Wolfbeis et al. Fluorimetric assay of hydrolases at longwave excitation and emission wavelengths with new substrates possessing unique water solubility
TR200002543T2 (tr) Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar
DE69814685D1 (de) Indolderivate als PKC-Inhibitoren
JP2002513761A5 (cg-RX-API-DMAC10.html)
AU3602499A (en) Indole derivatives suitable to be used as chromogenic compounds
DE60014960D1 (de) Alizarin-derivate als neue chromogene substrate
BR0010448A (pt) éster de morfolino-n-etila derivado de um inibidor de spla2 de indol
NO20020969L (no) Fremgangsmåte ved fremstilling av gallesyrederivater
TR200200995T2 (tr) 7-amino-3-metksimetil-3-sefem-4-karbosilik asitin hazırlanmasına yönelik proses.
TR200401456T1 (tr) Sitalopram hazırlanması için yöntem.
JPH10227755A5 (cg-RX-API-DMAC10.html)
AU5209600A (en) Orally active androgens
BR0208513A (pt) Processo de preparação de benazepril
TR200402142T4 (tr) (3-siyano-1H-indol-7-il) [4-(4-florofenetil)piperazin-1-il]-metanon ve bunların tuzlarının hazırlanması için işlem